Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Population pharmacokinetics of enoxaparin during the antenatal period.

Patel JP, Green B, Patel RK, Marsh MS, Davies JG, Arya R.

Circulation. 2013 Sep 24;128(13):1462-9. doi: 10.1161/CIRCULATIONAHA.113.003198. Epub 2013 Aug 12.

PMID:
23940396
[PubMed - indexed for MEDLINE]
2.

Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?

Kopelman TR, O'Neill PJ, Pieri PG, Salomone JP, Hall ST, Quan A, Wells JR, Pressman MS.

Am J Surg. 2013 Dec;206(6):911-5; discussion 915-6. doi: 10.1016/j.amjsurg.2013.10.005. Epub 2013 Oct 22.

PMID:
24296098
[PubMed - indexed for MEDLINE]
3.

Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy.

Ellison J, Walker ID, Greer IA.

BJOG. 2000 Sep;107(9):1116-21.

PMID:
11002955
[PubMed - indexed for MEDLINE]
4.

Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.

Shapiro NL, Kominiarek MA, Nutescu EA, Chevalier AB, Hibbard JU.

Pharmacotherapy. 2011 Jul;31(7):678-85. doi: 10.1592/phco.31.7.678.

PMID:
21923455
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.

Rojas L, Aizman A, Ernst D, Acuña MP, Moya P, Mellado R, Cerda J.

Thromb Res. 2013;132(6):761-4. doi: 10.1016/j.thromres.2013.10.005. Epub 2013 Oct 12.

PMID:
24521789
[PubMed - indexed for MEDLINE]
6.

Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.

Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A.

Thromb Haemost. 2001 Dec;86(6):1374-8.

PMID:
11776302
[PubMed - indexed for MEDLINE]
7.

Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series.

Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA.

BJOG. 2002 Sep;109(9):1020-4.

PMID:
12269676
[PubMed - indexed for MEDLINE]
8.

Bioactivity of enoxaparin in critically ill patients with normal renal function.

Gouya G, Palkovits S, Kapiotis S, Madl C, Locker G, Stella A, Wolzt M, Heinz G.

Br J Clin Pharmacol. 2012 Nov;74(5):806-14.

PMID:
23227470
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.

Fox NS, Laughon SK, Bender SD, Saltzman DH, Rebarber A.

Obstet Gynecol. 2008 Oct;112(4):884-9. doi: 10.1097/AOG.0b013e31818638dc. Erratum in: Obstet Gynecol. 2009 Mar;113(3):742.

PMID:
18827132
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.

Ní Ainle F, Wong A, Appleby N, Byrne B, Regan C, Hassan T, Milner M, Sullivan AO, White B, O'Donnell J.

Blood Coagul Fibrinolysis. 2008 Oct;19(7):689-92. doi: 10.1097/MBC.0b013e32830b14ef.

PMID:
18832911
[PubMed - indexed for MEDLINE]
11.

Adequate thromboprophylaxis in critically ill patients.

Levi M.

Crit Care. 2010;14(2):142. doi: 10.1186/cc8949. Epub 2010 Apr 21.

PMID:
20423535
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses.

Schwarzwald CC, Feige K, Wunderli-Allenspach H, Braun U.

Am J Vet Res. 2002 Jun;63(6):868-73.

PMID:
12061534
[PubMed - indexed for MEDLINE]
13.

Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.

Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G.

Br J Clin Pharmacol. 2005 Oct;60(4):364-73. Erratum in: Br J Clin Pharmacol. 2005 Oct;60(4):455.

PMID:
16187968
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.

Brieger D, Dawes J.

Thromb Haemost. 1997 Feb;77(2):317-22.

PMID:
9157589
[PubMed - indexed for MEDLINE]
15.

Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy.

Lebaudy C, Hulot JS, Amoura Z, Costedoat-Chalumeau N, Serreau R, Ankri A, Conard J, Cornet A, Dommergues M, Piette JC, Lechat P.

Clin Pharmacol Ther. 2008 Sep;84(3):370-7. doi: 10.1038/clpt.2008.73. Epub 2008 Apr 23.

PMID:
18431408
[PubMed - indexed for MEDLINE]
16.

Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.

Kinori M, Saar N, Justo D, Almog R.

Thromb Res. 2008;122(2):289-90; author reply 291. doi: 10.1016/j.thromres.2007.11.010. Epub 2008 Feb 21. No abstract available.

PMID:
18178242
[PubMed - indexed for MEDLINE]
17.
18.

Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.

Ma JM, Jackevicius CA, Yeo E.

Ann Pharmacother. 2004 Oct;38(10):1576-81. Epub 2004 Aug 24.

PMID:
15328396
[PubMed - indexed for MEDLINE]
19.

Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.

Freeman A, Horner T, Pendleton RC, Rondina MT.

Am J Hematol. 2012 Jul;87(7):740-3. doi: 10.1002/ajh.23228. Epub 2012 May 6.

PMID:
22565589
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.

Gibson JL, Ekevall K, Walker I, Greer IA.

Br J Obstet Gynaecol. 1998 Jul;105(7):795-7.

PMID:
9692422
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk